PositiveID to Launch Bluetooth Version of its Caregiver Non-Contact Thermometer by Early 2017

DELRAY BEACH, Fla., Sept. 13, 2016 -- PositiveID Corporation (“PositiveID” or “Company”) (OTCQB:PSID), a life sciences company focused on detection and diagnostics, announced today that it expects to launch a Bluetooth® version of its FDA-cleared Caregiver® infrared, non-contact thermometer by early 2017.  The Bluetooth-enabled Caregiver is designed to connect wirelessly to electronic health record (EHR) systems and other hospital equipment such as patient monitoring stations.

The new Caregiver Bluetooth-enabled thermometer uses the latest low energy version Bluetooth 4.0 known as “Bluetooth Smart” for maximum battery life.  The standardized Bluetooth Health Thermometer profile is incorporated into Caregiver for maximum flexibility to automatically transmit measured temperature to a wide variety of hospital systems and telemedicine platforms.

Caregiver, which is FDA cleared for clinical use, is a professional grade, infrared thermometer for measurement of forehead temperature in adults, children, and infants, without contact. It delivers an oral-equivalent temperature directly from the forehead in one to two seconds. Since there is no skin contact and Caregiver does not require probe cover supplies, it reduces the risk of cross-contamination, which is an increasing concern, and saves healthcare facilities the cost of covers (as much as $0.05 to $0.10 per temperature), storage space, and waste disposal costs. It is estimated that Caregiver can offer savings of $250 or more per year per device in probe cover supplies alone.

“We constantly strive to improve our offerings within all of our business lines to equip our current and potential customers with the most advanced, best-in-class products,” said William J. Caragol, Chairman and CEO of PositiveID. “By maintaining a leading technological position in the temperature monitoring market with this latest Bluetooth-enabled model of Caregiver, we can help improve the standard of care for patients while simplifying the providers’ role as well.”

The global market for temperature monitoring devices is forecast to reach $1 billion by 2020, with infrared thermometers experiencing the fastest growth driven in part by concerns over the spread of highly infectious diseases like Ebola, according to Global Industry Analysts, Inc.

About PositiveID Corporation
PositiveID Corporation is a life sciences tools and diagnostics company with an extensive patent portfolio. PositiveID develops biological detection and diagnostics systems, specializing in the development of microfluidic systems for the automated preparation of and performance of biological assays. PositiveID is also a leader in the mobile technology vehicle market, with a focus on the laboratory market and homeland security. For more information on PositiveID, please visit http://www.psidcorp.com, or connect with PositiveID on Twitter, Facebook or LinkedIn.

Statements about PositiveID's future expectations, including the likelihood that the Company will launch a Bluetooth version of its FDA-cleared Caregiver infrared, non-contact thermometer by early 2017; the likelihood that since there is no skin contact and Caregiver does not require probe cover supplies, it reduces the risk of cross-contamination, which is an increasing concern, and saves healthcare facilities the cost of covers (as much as $0.05 to $0.10 per temperature), storage space, and waste disposal costs; the likelihood that Caregiver can offer savings of $250 or more per year per device in probe cover supplies alone; the likelihood that by maintaining a leading technological position in the temperature monitoring market with this latest Bluetooth-enabled model of Caregiver, the Company can help improve the standard of care for patients while simplifying the providers’ role as well; the likelihood that the global market for temperature monitoring devices is forecast to reach $1 billion by 2020, with infrared thermometers experiencing the fastest growth driven in part by concerns over the spread of highly infectious diseases like Ebola; constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include, without limitation, the Company’s ability to target the professional healthcare market, as well as other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on April 12, 2016, and 10-Qs filed on August 12, 2016, May 16, 2016, and November 12, 2015, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

Contacts:
PositiveID Corporation
Allison Tomek
(561) 805-8044
[email protected]

RedChip Companies
Jon Cunningham
(407) 644-4256
[email protected]